Ceptaris Therapeutics
Malvern · Founded 2002
About Ceptaris Therapeutics
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
Company Facts
- Founded: 2002
- Legal name: Ceptaris Therapeutics, Inc.
- Operating status: Acquired
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $64.8M
- Funding stage: M&A
- Last round: Series D (Jun 2012)
- Website: ceptaris.com
- Phone: +1 610-975-9290
Canonical: https://fsome.com/organization/ceptaris-therapeutics-8300822 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.